Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Resistance to β-lactam antibiotics is rapidly growing, substantially due to the spread of serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs), which efficiently catalyse β-lactam hydrolysis. Combinations of a β-lactam antibiotic with an SBL inhibitor have been clinically successful; however, no MBL inhibitors have been developed for clinical use. MBLs are a worrying resistance vector because they catalyse hydrolysis of all β-lactam antibiotic classes, except the monobactams, and they are being disseminated across many bacterial species worldwide. Here we review the classification, structures, substrate profiles, and inhibition mechanisms of MBLs, highlighting current clinical problems due to MBL-mediated resistance and progress in understanding and combating MBL-mediated resistance.

More information Original publication

DOI

10.1016/j.tim.2023.01.013

Type

Journal article

Publication Date

2023-07-01T00:00:00+00:00

Volume

31

Pages

735 - 748

Total pages

13

Keywords

antimicrobial resistance, inhibition mechanism, inhibitor classification, metallo-β-lactamase, β-lactam, Anti-Bacterial Agents, beta-Lactamase Inhibitors, Drug Resistance, Bacterial, beta-Lactamases, beta-Lactams